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Abstract
SARS-coronavirus (SARS-CoV) genome expression depends on the synthesis of a set of mRNAs, which presumably are
capped at their 59 end and direct the synthesis of all viral proteins in the infected cell. Sixteen viral non-structural proteins
(nsp1 to nsp16) constitute an unusually large replicase complex, which includes two methyltransferases putatively involved
in viral mRNA cap formation. The S-adenosyl-L-methionine (AdoMet)-dependent (guanine-N7)-methyltransferase (N7-
MTase) activity was recently attributed to nsp14, whereas nsp16 has been predicted to be the AdoMet-dependent
(nucleoside-29O)-methyltransferase. Here, we have reconstituted complete SARS-CoV mRNA cap methylation in vitro.W e
show that mRNA cap methylation requires a third viral protein, nsp10, which acts as an essential trigger to complete RNA
cap-1 formation. The obligate sequence of methylation events is initiated by nsp14, which first methylates capped RNA
transcripts to generate cap-0
7MeGpppA-RNAs. The latter are then selectively 29O-methylated by the 29O-MTase nsp16 in
complex with its activator nsp10 to give rise to cap-1
7MeGpppA29OMe-RNAs. Furthermore, sensitive in vitro inhibition assays
of both activities show that aurintricarboxylic acid, active in SARS-CoV infected cells, targets both MTases with IC50 values in
the micromolar range, providing a validated basis for anti-coronavirus drug design.
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Introduction
In 2003, the severe acute respiratory syndrome coronavirus
(SARS-CoV), which was likely transmitted from bats, was
responsible for a worldwide SARS-outbreak [1]. Coronaviruses
belong to the order Nidovirales and are characterized by the largest
positive-strand RNA ((+) RNA) genomes (around 30,000 nt)
known in the virus world. The enzymology of their RNA synthesis
is therefore thought to be significantly more complex than that of
other RNA virus groups [2,3,4]. The 59-proximal two-thirds of the
CoV genome (open reading frames 1a and 1b) are translated into
the viral replicase polyproteins pp1a and pp1ab (Figure 1), which
give rise to 16 nonstructural proteins (nsps) by co- and post-
translational autoproteolytic processing. The 39-proximal third
encodes the viral structural proteins and several so-called accessory
proteins, which are expressed from a set of four to nine
subgenomic (sg) mRNAs. The latter are transcribed from
subgenome-length minus-strand templates, whose production
involves a unique mechanism of discontinuous RNA synthesis
(reviewed by [5,6]). To organize their complex RNA synthesis and
genome expression, the CoV proteome includes several enzyme
activities that are rare or lacking in other (+) RNA virus families
(reviewed in [2]). In the years following the 2003 SARS outbreak,
bioinformatics, structural biology, (reverse) genetics and biochem-
ical studies have contributed to the in-depth characterization of
CoV nsps in general and those of SARS-CoV in particular [7].
Currently documented enzyme activities include two proteinases
(in nsp3 and nsp5; [8,9]), a putative RNA primase (nsp8; [10]), an
RNA-dependent RNA polymerase (nsp12; [11,12]), a helicase/
RNA triphosphatase (nsp13; [13,14]), an exo- and an endoribo-
nuclease (nsp14 and nsp15; [15,16], and an S-adenosyl-L-
methionine (AdoMet)-dependent (guanine-N7)-methyltransferase
(N7-MTase), which were proposed to play a role in the formation
of CoV mRNA caps (nsp14; [17]). Based on comparative sequence
analysis, nsp16 presumably encodes an AdoMet-dependent
mRNA cap (nucleoside-29O)-methyltransferase (29O-MTase)
[3,18,19]. For SARS-CoV nsp16, however, this enzyme activity
has remained elusive thus far, and experimental evidence for its
existence has only been obtained for the related feline coronavirus
(FCoV) nsp16 [18]. CoV nsps form the viral replication/
transcription complex (RTC), which is thought to localize to a
network of endoplasmic reticulum-derived, modified membranes
in the infected cell [20,21]. Protein-protein interactions were
proposed to be essential for the assembly of the RTC and may
therefore also regulate the activities of enzymes involved in viral
RNA synthesis.
Although the 59 ends of SARS-CoV mRNAs have not been
characterized yet, they are assumed to carry a cap structure. This
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subgenomic mRNAs of the coronavirus murine hepatitis virus
(MHV) [22,23] and the related equine torovirus (EToV or Berne
virus), which also belong to the Coronaviridae family [23,24]. The
mRNAs of both viruses were concluded to carry a 59-terminal cap
structure. Moreover, in the coronavirus and torovirus genome three
enzymes putativelyinvolved inmRNAcapping have been identified,
although they remain poorly characterised [13,14,17,18,19]. Cap
structures promote initiation of translation and protect mRNAs
against exoribonuclease activities [25,26,27]. The synthesis of the
cap structure in eukaryotes involves three sequential enzymatic
activities: (i) an RNA triphosphatase (RTPase) that removes the 59 c-
phosphate group of the mRNA; (ii) a guanylyltransferase (GTase)
which catalyzes the transfer of GMP to the remaining 59-
diphosphate terminus; and (iii) an N7-MTase that methylates the
cap guanine at the N7-position, thus producing the so-called ‘‘cap-0
structure’’,
7MeGpppN. Whereas lower eukaryotes, including yeast,
employa cap-0 structure,higher eukaryotesconvertcap-0 intocap-1
or cap-2 structures [25,26,28] by means of 29O-MTases, which
methylate the ribose 29O-position of the first and the second
nucleotide of the mRNA, respectively. RNA cap methylation is
essential since it prevents the pyrophosphorolytic reversal of the
guanylyltransfer reaction, and ensures efficient binding to the
ribosome[25,26].Inthecaseof (+) RNA viruses suchas alphaviruses
and flaviviruses, mutations in RNA cap methylation genes were
shown to be lethal or detrimental to virus replication
[29,30,31,32,33]. For coronaviruses, a functional and genetic
analysis performed on MHV temperature sensitive mutants
mapping to the N7-MTase domain of CoV nsp14 and in the 29O-
MTase nsp16 indicated that both are involved in positive-strand
RNA synthesis by previously formed replicase-transcriptase com-
plexes [11]. The importance of nsp14 and nsp16 for viral RNA
synthesis is further supported by data obtained by mutagenesis of
Figure 1. Genomic organization of CoV pp1a/pp1ab and location of the nsp14 and nsp16 mutants. The SARS-CoV genomic RNA is
translated in two large polyproteins, pp1a and pp1ab following a -1 ribosomal frame shift. The two polyproteins are then cleaved by viral proteases in
order to produce 16 nsps (nsp1 to nsp11 from pp1a and nsp1 to nsp16 from pp1ab). Positions of the point mutants used in this study are indicated.
White triangles are used for positions targeting exonuclease motifs of nsp14 and black triangles are used for positions targeting MTase motifs of
nsp14 and nsp16 (the putative AdoMet binding site of nsp14 and catalytic tetrad of nsp16).
doi:10.1371/journal.ppat.1000863.g001
Author Summary
In 2003, an emerging coronavirus (CoV) was identified as
the etiological agent of severe acute respiratory syndrome
(SARS). SARS-CoV replicates and transcribes its large RNA
genome using a membrane-bound enzyme complex
containing a variety of viral nonstructural proteins. A
critical step during RNA synthesis is the addition of a cap
structure to the newly produced viral mRNAs, ensuring
their efficient translation by host cell ribosomes. Viruses
generally acquire their cap structure either from cellular
mRNAs (e.g., ‘‘cap snatching’’ of influenza virus) or employ
their own capping machinery, as is supposed to be the
case for coronaviruses. mRNA caps synthesized by viruses
are structurally and functionally undistinguishable from
cellular mRNAs caps. In coronaviruses, methylation of
mRNA caps seems to be essential, since mutations in viral
methyltransferases nsp14 or nsp16 render non-viable virus.
We have discovered an unexpected key role for SARS-CoV
nsp10, a protein of previously unknown function, within
mRNA cap methylation. Nsp10 induces selective 29O-
methylation of guanine-N7 methylated capped RNAs
through direct activation of the otherwise inactive nsp16.
This finding allows the full reconstitution of the SARS-CoV
mRNA cap methylation sequence in vitro and opens the
way to exploit the mRNA cap methyltransferases as targets
for anti-coronavirus drug design.
SARS-CoV RNA-Cap MTases
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[17,30].
In the case of coronaviruses, the machinery putatively involved
in equipping both genome and subgenomic mRNAs with a cap-1
structure is thought to consist of (i) the multifunctional nsp13,
which may contribute the RTPase activity of the helicase domain
[13,34], (ii) a still unknown GTase, (iii) the C-terminal domain of
nsp14, which was recently identified as the N7-MTase [17] and
(iv) nsp16, the putative 29O-MTase [3,17,18].
Using mammalian and yeast two-hybrid systems as well as pull-
down assays, it was shown that SARS-CoV nsp14 and nsp16
specifically interact with nsp10 [35,36] suggesting that nsp10 may
play a role in the viral capping pathway. The crystal structure of
nsp10, a small RNA-binding protein that contains two zinc fingers,
was recently solved [37,38], but its role and mode of action in the
viral replicative cycle remains elusive. In view of the phenotype of
some mouse hepatitis virus (MHV) mutants, a role in viral RNA
synthesis was postulated [11,39], but other studies implicated
nsp10 in replicase polyprotein processing [40]. SARS-CoV nsp10
was also shown to bind single- and double-strand RNA and DNA
with low affinity and without obvious sequence specificity [37].
In this study, we report the discovery of a function for SARS-
CoV nsp10 as an essential factor to trigger full nsp16 29O-MTase
activity. We deciphered the RNA cap methylation sequence where
the guanine-N7-methylation by nsp14 necessarily precedes the
29O-methylation by the nsp10/nsp16 pair. The SARS-CoV
nsp10/nsp14/nsp16 trio constitutes an attractive target package
for antiviral drug discovery and design; and indeed nsp14 and
nsp16 seem to play an important role in viral replication
[11,17,30]. Accordingly, we set up sensitive inhibition tests for
both activities, validated by low IC50 values of known AdoMet-
dependent MTase inhibitors. Moreover, we show that aurintri-
carboxylic acid (ATA), which was shown to inhibit SARS-CoV
replication [41], targets both MTases indeed.
Results
SARS-CoV nsp14 is active as AdoMet-dependent N7-
MTase on short capped RNA substrates whereas the
nsp16 29O-MTase requires nsp10 as co-factor
Unlike flaviviruses, which use a single active site in the NS5
protein for both N7- and 29O-MTase activities [32,42], corona-
viruses presumably encode two separate MTases that catalyze the
last two steps in the formation of a methylated RNA-cap structure.
SARS-CoV nsp14 has been shown to be an RNA-cap N7-MTase
[17]. Sequence motifs that are canonical in 29O-MTases were
identified in nsp16 [3,19], but the experimental verification of the
MTase activity has not been reported, in contrast to FCoV nsp16,
for which a rather low activity could be demonstrated [18]. SARS-
CoV nsp10 was previously shown to interact with both nsp14 and
nsp16 [35,36], suggesting its involvement in RNA capping and/or
methylation. Consequently, we cloned and expressed both nsp10
and nsp16 in E. coli and purified both recombinant proteins, using
their N-terminal His6-tag, by metal affinity chromatography.
Nsp14 was expressed as a fusion protein with an intein tag at its C-
terminus. The nsp14-intein product was bound to a chitin affinity
column and the untagged protein was eluted after removal of the
tag by DTT treatment. All three proteins were further purified by
size exclusion chromatography. Upon SDS-PAGE, the purified
proteins migrated as single bands corresponding to their expected
molecular masses (nsp14: 57 kDa; His6-nsp16: 35 kDa, and His6-
nsp10: 15 kDa) (Figure 2A). The identity of the recombinant
proteins was confirmed by trypsin digestion and mass spectrom-
etry ((MALDI-TOF), data not shown).
Using the purified recombinant proteins, we first conducted in
vitro MTase assays on short capped RNA substrates methylated or
not at the N7-position of the guanine cap (
7MeGpppAC5 and
GpppAC5). We used all possible combinations of the three
proteins (nsp10, nsp14, and nsp16) and incubated them with the
substrate in the presence of the tritiated methyl donor [
3H]-
AdoMet. The extent of [
3H]-CH3 transfer was quantified after
reaction times of 5, 30, and 240 min by using a DEAE filter-
binding assay (see Materials and Methods). Figure 2B shows that
nsp14 methylated GpppAC5 in a time-dependent manner whereas
neither nsp16 nor nsp10 alone did. Apparently, the activity of
nsp14 was barely influenced by the presence of nsp10 or nsp16. In
addition, we observed that nsp14 did not methylate
7MeGpppAC5
(Figure 2C) suggesting that nsp14 methylates only the N7-position
of the cap structure. In contrast to nsp14, nsp16 catalyzed
methyltransfer to neither GpppAC5 nor to
7MeGpppAC5 under
these reaction conditions. Surprisingly, when nsp16 activity assays
were supplemented with nsp10, robust methylation of
7MeGpp-
pAC5 was observed (Figure 2C), but not of GpppAC5 (Figure 2B).
In control reactions, containing either nsp10 alone or nsp10
supplemented with nsp14 no
7MeGpppAC5-specific MTase activity
was detected (Figure 2C). When the GpppAC5 substrate was
incubated with a combination of nsp10, nsp14, and nsp16
(Figure 2B), the level of substrate methylation was enhanced
compared to reactions performed with nsp14 alone. After
overnight incubation of GpppAC5 with the three proteins, the
methyl incorporation reached a plateau and the incorporation
level was twice higher than after a reaction in the presence of
nsp14 alone (not shown). In contrast, no significant difference was
observed between the methylation level reached after incubation
of the
7MeGpppAC5 substrate with either all three proteins or the
nsp16-nsp10 pair only (Figure 2C). Taken together, these results
suggest that, (i) SARS-CoV nsp14 methylates GpppAC5 at the N7-
position of the cap guanine and indeed acts as an N7-MTase on
these substrates, (ii) nsp16 acts as an nsp10-dependent 29O-MTase
on
7MeGpppAC5, (iii) the 29O-MTase activity of nsp16-nsp10
requires the presence of a cap structure already methylated at its
N7-position and (iv) nsp14 and the nsp16-nsp10 pair can perform
sequential double methylation of GpppAC5, presumably at the
N7- and 29O-positions.
To determine how nsp10 stimulated nsp16 MTase activity, we
co-expressed in E. coli an N-terminally Strep-tagged nsp10 and a
His6-tagged nsp16. The bacterial cell lysate containing these
proteins was incubated with Strep-Tactin beads (see Materials and
Methods), in order to bind the tagged nsp10. After extensive
washing, the proteins bound to the beads were analysed using
SDS-PAGE. Figure 2D indicates that nsp16 remained associated
with nsp10, whereas nsp16 alone was unable to bind to the beads.
These data suggest that nsp10 can stimulate the MTase activity of
nsp16 by direct association resulting in the formation of a nsp10/
nsp16 complex. When the intensities of the bands corresponding
to nsp10 and nsp16 were quantified, a ratio of nsp10 to nsp16 of
1.1 was obtained. Correcting for the respective molecular masses,
and assuming that they bind Coomassie blue dye with the same
affinity, this yields a nsp10 to nsp16 ratio of about 2.3. This
suggests that the complex does not contain a large molar excess of
nsp10, as one might have expected due to the fact that nsp10
seems to form dodecamers under certain conditions [38].
mRNA cap N7- and 29O-site specific methylation by
SARS-CoV nsp14 and nsp10/nsp16
In order to test MTase activities of nsp14 and nsp10/nsp16 on
virus-specific capped RNA substrates, we synthesized a 59-
triphosphate-carrying RNA corresponding to the first 264
SARS-CoV RNA-Cap MTases
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polymerase. Since the canonical T7 promoter inefficiently directs
transcription of RNA beginning with an A, as is required to make
transcripts resembling the 59 end of coronavirus RNAs, we used
the T7 class II w2.5 promoter [43]. Additionally, we introduced a
URG substitution in the 2
nd position of the RNA to increase the in
vitro transcription efficiency (data not shown). The RNA was
capped with [a-
32P]-GTP using the vaccinia virus (VV) capping
enzyme (containing RTPase, GTase and N7-MTase activities, see
Materials and Methods) in the presence or absence of the methyl
donor AdoMet. The substrates GpppAG-SARS-264 and
7MeGpp-
pAG-SARS-264 were then incubated with various combinations
of nsp14, nsp16, and nsp10. Reaction products were digested by
nuclease P1 in order to release the RNA cap structure.
Radiolabeled cap molecules were subsequently separated on
TLC plates and visualized using autoradiography. The compar-
ison with commercially available and in-house synthesized cap
analogs allowed the identification of the methylation position of
the cap structure. Figure 3A shows that the cap structure released
after nuclease P1 digestion of substrates GpppAG-SARS-264 and
7MeGpppAG-SARS-264 RNA co-migrated, as expected, with
GpppA and
7MeGpppA cap analogs, respectively. In the presence
of nsp14, or the VV:N7-MTase positive control, the GpppA cap
structure present at the 59 end of the RNA was converted into
7MeGpppA (left panel of Figure 3A). We also observed that the
methylation of the N7-position induced by nsp14 was weakly
stimulated in the presence of nsp10, but was not influenced by the
presence of nsp16. Indeed, nsp14 converts 83% of the substrate
into the
7MeGpppA product, whereas in the presence of nsp10
97% of the substrate was converted, as judged by autoradiography
analysis. Nsp10 or nsp16 alone did not show any MTase activity.
When all three proteins are present, the substrate is fully
methylated at the N7- and 29O-positions of the cap, as judged
by the comparison with products generated by the bifunctional
N7- and 29O-MTase domain of dengue virus protein NS5
(DV:NS5MTase), which was used as a positive control [32,42].
The right panel of Figure 3A shows that incubation of
7MeGpppAG-SARS-264 RNA, with nsp14, nsp16 or nsp10 alone
did not result in 29O-methylation of the
7MeGpppA structure. The
same was true when nsp14/nsp10 or nsp14/nsp16 combinations
were tested. In contrast, 29O-methylation of the cap structure of
7MeGpppAG-SARS-264 occurred upon incubation with nsp10/
nsp16, and also when all three proteins were used together. We
therefore conclude that capped RNA corresponding to the first
264 nucleotides of the SARS-CoV genome represents a bona fide
substrate to follow the RNA cap MTase activities of SARS-CoV
nsp14 and nsp10/nsp16. Moreover, the TLC analysis allowed us
to demonstrate that nsp14 indeed specifically methylates RNA cap
structures at the N7-position and that nsp10/nsp16 methylates
capped RNA at the 29O-position of the first nucleotide after the
Figure 2. SARS-CoV proteins nsp14, nsp16 and nsp10 purifi-
cation, AdoMet-dependent MTase activity on short capped
RNA and complex formation of nsp16/nsp10. Panel A: The SARS-
CoV proteins nsp14, nsp16 and nsp10, purified by affinity and size
exclusion chromatography (as described in Materials and Methods)
were separated by SDS-PAGE (14%) and visualized by Coomassie blue
staining. Lane 1 corresponds to the molecular size markers, lanes 2 to 4
to nsp14, nsp16, and nsp10, respectively. Panel B and C: AdoMet-
dependent MTase assays performed on short capped RNA substrates.
The different purified proteins (nsp10: 1200 nM, nsp14: 50 nM and
nsp16: 200 nM) were incubated with GpppAC5 and
7MeGpppAC5 RNA
oligonucleotides in presence of [
3H]-AdoMet as described in Materials
and Methods. The methyl transfer to the capped RNA substrate was
determined after 5-, 30-, and 240-min incubation by using a filter-
binding assay (see Materials and Methods). Panel D: SARS-CoV His6-
nsp16 protein co-expressed with strep-tag-nsp10 and His6-nsp16
expressed alone were incubated with Strep-Tactin sepharose. Strep-
Tactin-bound protein was eluted with D-desthiobiotin and analysed by
SDS-PAGE and Coomassie blue staining. Lane 1 corresponds to the
molecular size markers, lane 2 to strep-tag-nsp10 co-expressed with
His6-nsp16 and lane 3 to His6-nsp16 alone.
doi:10.1371/journal.ppat.1000863.g002
SARS-CoV RNA-Cap MTases
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nsp10/nsp16 could only methylate
7MeGpppAG-SARS-264 and not
GpppAG-SARS-264, suggesting that N7-methylation by nsp14 must
precede 29O-methylation by nsp10/nsp16. We conclude that nsp14
exhibits N7-MTase activity in the absence of nsp10, whereas the latter
is an absolute requirement for nsp16-mediated 29O-methylation of the
cap structure. Nsp10, which was previously shown to interact with both
nsp14 and nsp16 [35,36], modestly stimulates the nsp14-mediated cap
N7-MTase activity (Figure 3A and S1B; 10 to 15% increase of activity
at a broad optimum around a 4-fold molar excess).
Figure 3. AdoMet-dependent MTase assays of nsp14 and nsp16/nsp10 on long, virus-specific, capped RNA substrates. Panel A:
Capped RNAs corresponding to the first 264 nucleotides of the SARS-CoV genome were incubated with SARS-CoV proteins (nsp10: 1.2 mM, nsp14:
50 nM and nsp16: 200 nM). Labeled substrates G*pppAG-264 or
7MeG*pppAG-264 RNA (the asterisk indicates the labeled phosphate) were incubated
alone or in presence of the indicated proteins, digested by nuclease P1 and analyzed by TLC. The origins and the positions of standards GpppA,
7MeGpppA,
7MeGpppA2’OMe and GpppA2’OMe (see Materials and Methods) are indicated by black arrows. VV:N7-MTase stands for vaccinia virus N7-
MTase and DV:NS5MTase for dengue virus MTase domain of protein NS5, a bi-functional N7- and 29O-MTase, which were used as positive controls.
Panel B: Time course analysis of the N7- and 29O-methylation by nsp14 and nsp16/nsp10. Labeled G*pppAG-SARS-264 RNA was incubated with a
mixture of nsp10 (1.2 mM), nsp14 (50 nM), and nsp16 (200 nM). Methylation of the cap structure was followed during 60 min. The final point
(overnight = ovn) corresponds to 20 h. As in panel A, TLC analysis of nuclease P1-resistant cap structures is shown. The positions of the origin of
migration and of GpppA,
7MeGpppA,
7MeGpppA2’OMe and GpppA2’OMe cap analog standards are indicated.
doi:10.1371/journal.ppat.1000863.g003
SARS-CoV RNA-Cap MTases
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methylation, we performed a time-course experiment using the
GpppAG-SARS-264 substrate in conjunction with nsp10, nsp14,
and nsp16. The results, shown in Figure 3B, indicate that
methylation of the substrate indeed starts at the N7-position.
Subsequently, the
7MeGpppA cap-0 structure is converted to an
7MeGpppA2’OMe cap-1 structure. A GpppA2’OMe structure was
never observed in this assay, not even when using larger amounts
of nsp10/nsp16 or nsp16 (data not shown), in agreement with the
data presented in Figures 2B and 3A that show that GpppAC5 and
GpppAG-SARS-264 substrates are not methylated by nsp10/
nsp16. Thus, the N7-methylation of the SARS-CoV cap structure
by nsp14 is a pre-requisite for its recognition by the nsp10/nsp16
pair, which then converts the cap-0 into a cap-1 structure by 29O-
methylation.
The nsp14 D331 residue is essential for N7-methylation
whereas catalytic residues of the N-terminal exonuclease
domain are not
The recent identification of the C-terminal domain of nsp14 as
an N7-MTase [17] revealed that this replicase subunit is a
multifunctional protein, since it also carries an exoribonuclease
activity embedded in its N-terminal domain [16]. The interplay
between these two functionalities was analyzed using mutagenesis
experiments. We mutated conserved residues in both the MTase
and the exoribonuclease domain to evaluate the possible interplay
or long-range regulation of both activities. The conserved residue
D331, which is presumably involved in AdoMet-binding, was
mutated to alanine. In the exoribonuclease domain, we replaced
conserved residues from exonuclease motifs I (D90XE92), II (D243)
and III (D273 and H268) of the DE(A/D)D nuclease superfamily.
All the His-tagged nsp14 mutant proteins could be expressed,
except the D243A mutant, which was barely soluble. Figure 4A
shows that they migrated at a molecular mass similar to that of wt
nsp14 upon SDS-PAGE. We next analyzed their N7-MTase
activity on GpppAC5 using [
3H]-AdoMet as methyl donor. The
results show that the D331A point mutation completely abolished
nsp14 N7-MTase activity. This is in agreement with the
hypothesis [17] that the MTase domain is located in the C-
terminal half of nsp14 protein and that the conserved residue D331
is important for N7-MTase function. In contrast, the mutations in
the exonuclease domain did not significantly interfere with nsp14
MTase activity, excepted in the case of the motif I-double mutant
(D90XE92) which displayed attenuated N7-MTase activity (,2-
fold). This observation is in agreement with the fact that a N-
terminal truncation of 90 amino acids of the nsp14 exoribonu-
clease domain abolished the N7-MTase activity in a yeast trans-
complementation assay [17]. Thus an altered N-terminus of the
exoribonuclease domain may still interfere with the MTase activity
to a certain extent.
Identification of K46-D130-K170-E203 as a catalytic tetrad in
SARS-CoV nsp16
In order to ascertain that nsp16 supports the 29O-MTase
activity and not the nsp10 protein, we engineered and character-
ized a set of nsp16 point mutations. We mutated the conserved
residues K46-D130-K170-E203, which form the canonical catalytic
tetrad of mRNA cap 29O-MTases [42,44]. The putative catalytic
residues of SARS-CoV nsp16 were identified using sequence
alignment with the homologous FCoV nsp16 29O-MTase and
other family members [18]. Three of the four alanine point
mutants could be expressed as efficiently as wt nsp16, allowing
their purification to homogeneity using a single-step of affinity
chromatography (see Materials and Methods). Still, smaller
amounts of the fourth mutant (K46A) could also be produced
and purified. We obtained sufficient soluble protein to perform
MTase assays, although protein yield and purity were lower than
for the other mutants (Figure 4B). For all mutant proteins, the
29O-MTase activity was tested on
7MeGpppAC5 and compared to
that of the wt nsp16/nsp10 control pair. The 29O-MTase activity
was indeed completely abolished by any single mutation of the
putative K46-D130-K170-E203 catalytic tetrad residues of nsp16.
This result demonstrated that although nsp10 stimulates the 29O-
MTase activity by a yet unknown mechanism, the catalytic activity
itself resides in nsp16.
Inhibition of MTase activities of SARS-CoV nsp14 and
nsp16/nsp10
Viral MTases exhibit many original features relative to their
host cell MTase counterparts, and are increasingly explored as
putative targets for the development of antivirals [45]. In order to
set up sensitive N7- and 29O-MTase inhibition tests, we
determined more precisely the conditions to measure optimum
MTase activity for nsp14 and nsp16/nsp10 using their respective
substrates GpppAC5 and
7MeGpppAC5 (see Text S1). We thus
defined the following standard assay conditions: the N7-MTase
activity of nsp14 was measured in presence of 40 mM Tris-HCl,
pH 8.0 and 5 mM DTT. For the 29O-MTase assays, the same
buffer was used together with 1 mM of MgCl2. As Figure S1B
illustrates, nsp10 stimulates nsp16 29O-MTase activity in a dose-
dependent manner. We used a 6-fold molar excess of nsp10 over
nsp16 corresponding to <75% of the maximal stimulation that
could be achieved.
Inhibition was tested for two AdoMet analogs with documented
mRNA cap MTase inhibition properties: AdoHcy (S-adenosyl-l-
homocysteine), the co-product of methyl transfer, and sinefungin
[18,46,47,48,49]. We also used compounds known to target other
AdoMet-dependent MTases, such as SIBA, 3-deaza-adenosine
[50] and MTA [51]. Based on their adenosine or guanosine-
containing structures, adenosine- and AdoMet-analogs 29,39,59-tri-
O-acetyl-adenosine and S-59-adenosyl-L-cysteine were tested as
well as GTP,
7MeGTP, GTP- or cap-analogs (ribavirin and its
triphosphate as well as EICAR-triphosphate, GpppA and
7MeGpppA). Finally, we included two inhibitors of flavivirus
mRNA cap MTase activites: aurintricarboxylic acid (ATA), which
is expected to bind to the MTase active site [52], and a substituted
adamantane compound supposedly binding to the AdoMet-
binding site [53]. Interestingly, ATA has been shown recently to
inhibit SARS-CoV replication by an unknown mechanism of
action [41].
Nsp14 and nsp16/nsp10 were first incubated with 100 mMo f
each candidate inhibitor in the presence of [
3H]-AdoMet. N7- and
29O-MTase activities were determined by quantification of methyl
transfer to the GpppAC5 and
7MeGpppAC5 RNA substrates,
respectively. As shown in Figure 5A, 10 out of 16 tested molecules
barely inhibited the SARS-CoV MTases. Cap analogs (GpppA and
7MeGpppA) showed limited (50%) inhibition capacity on both
SARS-CoV MTases. In contrast, we observed that AdoHcy,
sinefungin and ATA efficiently inhibited both enzymes at
100 mM. The IC50 values of AdoHcy were 16 and 12 mM for the
N7- and 29O-MTase activities, respectively (Figure 5B) ten-fold
higher than Ki values reported for VV:N7- and 29O-MTases (1 and
0.5 mM, respectively, [47]). Sinefungin, a potent inhibitor of
VV:N7- and 29O-MTases with reported IC50 values of 12.0 and
39.5 nM, respectively [46], showed the most potent inhibition
profile on nsp14 and nsp10/nsp16 with IC50 values of 496 nM and
736 nM, respectively (Figure 5C). These values are similar to the
SARS-CoV RNA-Cap MTases
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DV:NS5MTase (420 nM [49] and 630 nM [48]). The obtained
IC50 values of ATA for SARS-CoV nsp14 and nsp10/nsp16 were
6.4 mM and 2.1 mM, respectively (Figure 5D). These results
demonstrate that sensitive assays are now available to discover
andcharacterizeinhibitors of the SARS-CoV N7-and 29O-MTases
rendering low IC50 values of known AdoMet-dependent MTase
inhibitors like AdoHcy and sinefungin. Moreover we have shown
that nsp14 and nsp16 MTases are two putative targets of ATA, that
was shown to inhibit SARS-CoV replication in infected cells [41].
Figure 4. Alanine mutagenesis of nsp14 and nsp16 proteins. Panel A: Residues of the nsp14 exoribonuclease and MTase catalytic sites were
mutated to alanine as indicated in Materials and Methods. Equal amounts (50 nM) of each nsp14 mutant were incubated with GpppAC5 in the
presence of [
3H]-AdoMet. Methyl transfer to the RNA substrate was measured after 30 min by using a filter-binding assay (upper panel). The N7-
MTase activity of the wt control protein was arbitrarily set to 100%. The bar graph presents the results of 3 independent experiments. The purified
His6-tagged proteins analyzed by SDS-PAGE (14%) are shown in the lower panel. Panel B: Each residue of the putative catalytic tetrad K46-D130-K170-
E203 of nsp16 was mutated to alanine. Equal amounts of the different nsp16 mutants (200 nM) were incubated with
7MeGpppAC5 in the presence of
[
3H]-AdoMet and nsp10 (1.2 mM). The methyl transfer to the RNA substrate was measured after 30 min by using a filter-binding assay. The 29O-MTase
activity of the wt protein in the presence of nsp10 was arbitrarily set to 100%. The bar graph represents the mean of 3 independent experiments. The
purified His6-tagged proteins analyzed by SDS-PAGE (14%) are shown in the lower panel.
doi:10.1371/journal.ppat.1000863.g004
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Enzymatic activities postulated to be involved in the SARS-CoV
RNA capping pathway were previously documented for the
ORF1b-encoded replicase subunits nsp13 (RNA 59- triphospha-
tase/helicase [13]) and nsp14 (N7-MTase [17]). Thus far, the
predicted 29O-MTase activity of nsp16 [3,19] could only be
verified for FCoV nsp16 [18]. Surprisingly, SARS-CoV nsp16
29O-MTase failed to exhibit activity under a wide range of
experimental conditions, including those used for FCoV nsp16
(not shown). In this study, we have characterized the MTase
activities of both SARS-CoV nsp14 and nsp16, and in particular
established that the in vitro activity of SARS-CoV nsp16 critically
depends on the presence of nsp10. The latter had no known role
or function, but was previously shown to interact with both MTase
proteins nsp14 and nsp16 [35,36].
Here, we show that the nsp14 AdoMet-dependent MTase
activity can methylate GpppAC5 RNA, but not a
7MeGpppAC5
substrate, indicating that nsp14 specifically targets the N7-position
of the guanine residue in the cap structure. This was verified using
a substrate mimicking the capped 59 end of the SARS-CoV
genome. Nuclease P1 enzymatic digestion and TLC analysis
confirmed the position of methylation by nsp14; and mutagenesis
of a predicted AdoMet binding site residue abolished N7-MTase
activity. We therefore conclude that nsp14 alone can act as an
AdoMet-dependent MTase that specifically targets the N7-
position of the cap structure, thus converting GpppRNA into
7MeGpppRNA. These results confirm and extend the recently
described observations on the cap N7-MTase activity of SARS-
CoV nsp14 in vitro and in a yeast-based complementation system
[17].
In contrast to nsp14, bacterially expressed SARS-CoV nsp16 is
less stable, reluctant to crystallization (not shown), and inactive on
7MeGpppRNA and GpppRNA in our in vitro assays. We report
here that SARS-CoV nsp16 forms a complex with nsp10 that is
endowed with robust and long-lived MTase activity. In contrast,
FCoV nsp16 by itself was shown to possess 29O-MTase activity
under similar reaction conditions, but at much higher enzyme
concentration (SARS-CoV: 200 nM; FCoV: 3 mM [18]). This
suggests that FCoV nsp16 might also need FCoV nsp10 for its
proper activation. As in the case of FCoV nsp16, SARS-CoV
nsp16 in the presence of nsp10, specifically methylates capped
RNAs carrying a methyl group at the N7-guanine position,
allowing the conversion of cap-0 into cap-1 structures. Using
7MeGpppAG-RNA corresponding to the 59 end of the SARS-CoV
genome, we have confirmed that nsp10/nsp16 catalyzes the
transfer of a methyl group from the AdoMet donor to the 29O-
Figure 5. Inhibition of the nsp14 and nsp16/nsp10 MTase
activities. Nsp14 (50 nM) and nsp16/nsp10 (200 nM/1.2 mM) were
incubated with GpppAC5 (in grey) and
7MeGpppAC5 (in black),
respectively, in order to measure the methyl transfer to the RNA
substrates by filter-binding assay (see Materials and Methods). Panel A:
Methyl transfer was measured at a final concentration of 100 mMo f
each inhibitor candidate. The outcome of the control reaction in
absence of inhibitor and at 5% of DMSO was set to 100%. The mean
value of three independent experiments is given. 1: control, 2: AdoHcy,
3: sinefungin, 4: SIBA (59-S-isobutylthio-59-deoxyadenosine), 5: 3-deaza-
adenosine, 6: MTA (59-deoxy-59-methylthio-adenosine), 7: 29,39,59-tri-O-
acetyl-adenosine, 8: S-59-adenosyl-L-cysteine, 9: GTP, 10:
7MeGTP, 11:
ribavirin, 12: ribavirin-triphosphate, 13: EICAR-triphosphate, 14: GpppA,
15:
7MeGpppA, 16: ATA, 17: adamantane-analog (N-({[3-(4-methylphe-
nyl)-1-adamantyl]amino}carbonyl)phenylalanine). Panels B, C and D:
Dose-response curves and IC50 values of inhibitors AdoHcy, sinefungin
and ATA, respectively. The results of three independent experiments are
given. Standard deviations are shown for concentrations that were
tested three times. IC50 values were calculated as described in Materials
and Methods.
doi:10.1371/journal.ppat.1000863.g005
SARS-CoV RNA-Cap MTases
PLoS Pathogens | www.plospathogens.org 8 April 2010 | Volume 6 | Issue 4 | e1000863position of the first nucleotide after the cap guanosine. Finally, the
intrinsic nsp16 29O-MTase activity was corroborated by muta-
genesis of its predicted, canonical catalytic tetrad K46-D130-K170-
E203 [3,18,19].
The interplay between nsp10 and the nsp16 MTase
The nsp10 protein was previously proposed to play a role in
viral RNA synthesis [11,39,40] and replicase polyprotein process-
ing [40] on the basis of the analysis of MHV nsp10 mutants. In
this work, we propose a new function for nsp10 as a regulator of an
enzyme involved in the methylation of cap structures. Our
observation seems not directly related to the phenotype previously
described for nsp10 mutants [11,39,40]. Nevertheless, RNA cap
methylation defects should limit RNA stability and may therefore
contribute to a decrease in viral RNA synthesis observed in MHV
mutants [11,39,40]. Here, we show that nsp10 itself is catalytically
inert in methylation reactions (Figures 2, and 3) and that it forms a
complex with nsp16 (Figure 2C). Interestingly, whereas at least a
10-fold molar excess of nsp10 is required for maximal stimulation
of nsp16 (Figure S1B), quantification of the protein bands of nsp10
and nsp16 in the purified complex indicates a maximum ratio of
2.3 (Figure 2D). We assume that, under conditions of maximal
stimulation, nearly all nsp16 molecules are associated with one or
two nsp10 molecules. Considering that the reaction mixture at
50% stimulation contained 200 nM of nsp16 and around 400 nM
of nsp10 (Figure S1B), the dissociation constant of the nsp10/
nsp16 complex can roughly be estimated to be in the order of
400 nM for a 1:1 complex or 200 nM for a 2:1 complex. This is in
agreement with a Kd of 250 nM determined by plasmon surface
resonance analysis (Lecine P. personal communication).
What could be the mechanism of nsp16 activation by nsp10?
Nsp10 may increase the stability of nsp16, stabilize the nsp16
RNA binding groove, contribute to RNA substrate binding and/
or allosterically regulate its substrate affinity and activity. Similar
activation of an MTase involved in the capping pathway was
previously reported for the VV capping enzyme [54]. The
catalytic efficiency of the N7-MTase domain of the VV:D1
protein was 370-fold stimulated by addition of an equimolar
concentration of the small VV:D12 protein, which does not
contain any catalytic residues [55]. Activation is achieved through
increase of substrate and co-substrate affinity as well as of the turn
over number. At the same time, VV:D12 exerts a stabilizing effect
on VV:D1 [55]. The determination of the crystal structure of the
protein complex VV:D1/D12 [56] revealed that the VV:D12
protein is structurally homologous to the cap 29O-MTase of
reovirus, with a truncation of the AdoMet binding domain. The
SARS-CoV nsp10 crystal structure did not reveal any similarity to
an MTase fold nor to any protein in the Protein Data Bank (PDB)
[37,38], but the activating effect of nsp10 on nsp16 might also be
exerted on different levels via allosteric activation by increasing
substrate affinity and/or turn over number, and/or by stabiliza-
tion of nsp16.
The presence of two Zn fingers is a major structural feature of
nsp10 that is likely related to its biological functions, since Zn
fingers typically function as interaction modules binding to
proteins, nucleic acid and small molecules [57]. Interestingly,
several MTases have previously been shown to be regulated
through specific interactions with Zn finger domains [58,59].
Since the first Zn finger of nsp10 lies in a positively charged
surface patch, it might be involved in the low affinity interaction of
nsp10 with single- and double-strand RNA and DNA [37]. The
affinity of nsp10 for single–stranded RNA appears too weak to
explain a direct role in RNA recruitment for nsp16 [36]. We
expect that SARS-CoV nsp16 contains a specific binding site for a
cap-0 structure followed by a small stretch of 3 to 4 nucleotides as
predicted for FCoV nsp16 from enzymatic assays [18]. The
formation of the complex nsp10/nsp16 might provide a longer
substrate-binding site and in that way enhance affinity of nsp16 for
its RNA substrate. Nevertheless, given the fact that the full
activation effect by nsp10 is also seen when short substrates
containing the cap and 5 nucleotides are used, we surmise that
extension of the RNA binding site is of minor importance. Further
work is needed in order to understand the molecular basis of nsp16
activation by nsp10.
Coronavirus mRNA cap methylation
There are indications that CoV genomic RNAs and sub-
genomic RNAs carry a 59-terminal cap-1 structure (see Introduc-
tion) and three of four putative cap-forming enzyme functions
required to produce this structure have now been identified for
SARS-CoV (nsp13, nsp14, and nsp16) [3,17,18]. The CoV cap
structure methylation seems to follow the ‘‘classic’’ sequence of
N7-methylation preceding the 29O-methylation. The modular
structure of two separate single-domain enzymes corresponds to
the scenario in metazoan and plants [25,26]. It contrasts to
dsRNA reoviruses where one multi-domain protein contains two
MTase domains [60] and to flaviviruses and negative-strand RNA
((-) RNA) vesiculoviruses where both MTase activites reside in a
single domain of larger proteins and use a single active site [32,61].
A characteristic feature of CoV MTases is that nsp14 recognizes
non-methylated RNA cap exclusively, and nsp10/nsp16 recog-
nizes N7-methylated RNA cap exclusively. In contrast, bi-
functional MTases recognize both non-methylated and methylated
cap structures with equal affinity [48,62,63]. Interestingly, the
flaviviral N7-MTase activity is regulated by specific 59-proximal
viral RNA secondary structures and both N7- and 29O-MTase
activities seem to require in particular the terminal dinucleotide
AG [32,64]. Since the SARS-CoV nsp14 N7-MTase activity can
complement N7-MTase defects in yeast, [17], it suggests that
specific sequences and/or RNA structures are not required for this
activity. This was confirmed in our in vitro assays, where both N7-
and 29O-methylation was observed using small GpppAC5 RNA
substrates that do not correspond to the natural sequence present
at the 59 end of CoV mRNAs. Nevertheless, the CoV capping
machinery is likely to act specifically on viral mRNA substrates,
which present a common 59-terminal leader sequence (72
nucleotides long in the case of SARS-CoV [4]). The mechanism
to achieve this selectivity may depend on the GTase reaction or on
the fine regulation of capping enzymes by protein-protein
interactions within the replication and transcription complex.
The regulation of the 29O-MTase activity of nsp16 by the small
nsp10 protein is clearly an original feature of CoV mRNA cap
methylation.
Coronavirus MTases as potential targets for antiviral
inhibitors
Virally encoded RNA cap N7- and 29O-MTase activities have
been identified in various virus families, such as dsDNA poxviruses
[65,66], dsRNA reoviruses [67,68], (-) RNA viruses such as
vesicular stomatitis virus [61], and (+) RNA viruses like flaviviruses
[33,42,69]. For many of them, including coronaviruses [17,30], it
has been shown that mutations abolishing the N7-MTase activity
have a clear detrimental effect on replication [32], whereas 29O-
MTase knockouts exerted more moderate effects [32,33]. These
observations suggest that compounds specifically inhibiting cap
MTases could be potent antiviral agents. Although some viral
MTase inhibitors have also been reported to inhibit mammalian
MTases [70,71], sinefungin or other AdoMet analogs might have
SARS-CoV RNA-Cap MTases
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shown that sinefungin inhibits fungal mRNA cap N7-MTases with
5 to 10 times more potency than the human isoform [71].
Here, we report assays using GpppAC5 and
7MeGpppAC5
substrates that constitute sensitive screening tests for the
identification and characterization of inhibitors of the N7- and
29O-MTase activities, respectively, of SARS-CoV. We confirmed
this by obtaining low IC50 values of known AdoMet-dependent
MTase inhibitors AdoHcy and sinefungin. Furthermore, we found
that ATA, a compound previously reported as a putative blocker
of the catalytic site of NS5MTase of flaviviruses [52], and of
SARS-CoV replication in infected cells [41], inhibited both
SARS-CoV MTase activities with IC50 values of 2.1 and 6.4 mM,
respectively. Thus, we propose that nsp14 and nsp16/nsp10 are
two of the SARS-CoV targets of ATA leading, or at least
contributing, to the inhibition of SARS-CoV replication.
In conclusion, our results identify and characterize the main
viral protein players of SARS-CoV mRNA cap methylation. Its
specificity and mechanistic originality remain unparalleled thus far
and should open new avenues to investigate viral RNA capping, a
field that is increasingly permeable to drug design projects.
Materials and Methods
Reagents
AdoMetandcapanalogsGpppA and
7MeGpppAwere purchased
from New England BioLabs. The compounds tested as MTase
inhibitors were purchased from the following providers: Sigma-
Aldrich: AdoHcy (adenosine-homocysteine), GTP,
7MeGTP, 3-
deaza-adenosine, SIBA (59-S-isobutylthio-59-deoxyadenosine), sine-
fungin (adenosyl-ornithine), ribavirin (1-b-D-ribofuranosyl-1,2,4-
triazole-3-carboxamide), MTA (59-deoxy-59-methylthio-adenosine),
29,39,59-tri-O-acetyladenosine, S-59-adenosyl-L-cysteine, 1,2-(((3-(4-
methylpenyl)adamantine-1-yl)cabomoyl) and ATA (aurintricar-
boxylic acid); TriLink Biotechnologies: Ribavirin-triphosphate and
ribavirin. EICAR-(5-Ethynyl-1-b-D-ribofuranosylimidazole-4-car-
boxamide)-triphosphate was a kind gift from P. Herdewijn (Leuven,
Belgium). They were dissolved in H2O or DMSO as previously
described [18,52,53] and ATA was dissolved in 0.1 M NaOH as
described in [52]. Concentrations were set to 10 mM and
compounds stored at -20uC. All radioactive reagents were
purchased from Perkin Elmer.
Cloning of the SARS-CoV nsp10, nsp14 and nsp16 genes
The SARS-CoV nsp10-, nsp14-, and nsp16-coding sequences
were amplified by RT-PCR from the genome of SARS-CoV
Frankfurt-1 (accession number AY291315) as previously described
[72]. The nsp10, nsp14, and nsp16 genes (encoding residues
4231–4369, 5903–6429, and 6776–7073 of replicase pp1ab) were
cloned using Gateway technology (Invitrogen) into expression
vector pDest14 (pDest14/6His-nsp10, pDest14/6His-nsp14 and
pDest14/6His-nsp16) to produce recombinant proteins carrying
an N-terminal His6-tag. The nsp14 gene was also cloned into the
pTXB1 vector from the Impact kit (New England Biolabs) to
generate the pTXB1-nsp14 plasmid that allows the expression of
the nsp14 protein fused to the intein-chitin binding domain.
SARS-CoV nsp10/nsp16 complex was produced in E. coli in a
bi-promotor expression plasmid kindly provided by Bruno
Coutard (AFMB France). In this backbone, SARS CoV nsp10
can be expressed under a tet promoter and encodes a protein in
fusion with a N-terminal strep tag, whereas nsp16 is expressed
under a T7 promoter and encodes a protein in fusion with a N-
terminal hexa-histidine tag. The single point mutants of pDest14/
6His-nsp14 (the mutant numbering starts at the beginning of the
nsp14 sequence; D90A & E92A, H268A, H268L, D273A and
D331A) and the mutants of pDest14/6His-nsp16 (the mutant
numbering starts at the beginning of the nsp16 sequence; K46A,
D130A, K170A, E203A) were generated by PCR using the
Quickchange site–directed mutagenesis kit (Stratagene), according
to the manufacturer’s instructions.
Expression and purification of SARS-CoV nsp10, nsp14
and nsp16 proteins
E. coli C41 (DE3) cells (Avidis SA, France), containing the pLysS
plasmid (Novagen), were transformed with the various expression
vectors and grown in 2YT medium containing ampicillin and
chloramphenicol. Protein expression was induced by addition of
IPTG to a final concentration of 500 mM (nsp10) or 50 mM (nsp14
and nsp16), when the OD600 nm value of the culture reached 0.5.
Nsp10 expression was performed during 4 h at 37uC, whereas
nsp14- and nsp16-expressing bacteria were incubated during 16 h
at 17uC. Bacterial cell pellets were frozen and resuspended in lysis
buffer (50 mM HEPES, pH 7.5, 300 mM NaCl, 5 mM MgSO4,
5m M b-mercaptoethanol (only for nsp10) supplemented with
1 mM PMSF, 40 mM imidazole, 10 mg/ml DNase I, and 0.5%
Triton X-100. After sonication and clarification, proteins were
purified by two steps of chromatography except the nsp14
mutants, which were purified by one-step of IMAC (HisPurTM
Cobalt Resin; Thermo Scientific) and concentrated on 50-kDa
centrifugal filter units (Millipore).
Two-step purification of the His6-tagged proteins started with
IMAC (HisPurTM Cobalt Resin; Thermo Scientific) eluting with
lysis buffer supplemented with 250 mM imidazole. Protein
fractions were then loaded on a HiLoad 16/60 Superdex 200
gel filtration column (GE Healthcare), and eluted with 10 mM
HEPES, pH 7.5, 150 mM NaCl. The protein fractions were
concentrated to around 2 mg/ml and stored at 220uC in the
presence of 50% glycerol.
The nsp14 protein expressed in fusion with the intein-chitin
binding domain was purified on a chitin column using the
IMPACT kit (New England Biolabs). The bacterial lysate was
loaded onto the column, washed with 50 mM HEPES pH 7.5,
1 M NaCl and 0.5% Triton X-100. The column was then
incubated in 50 mM HEPES pH 7.5, 500 mM NaCl, 50 mM
DTT at 4uC for 48 hours in order to induce the intein cleavage.
Next, the protein was eluted in 50 mM HEPES pH 7.5, 1 M
NaCl buffer and subsequently purified on a HiLoad 16/60
Superdex 200 gel filtration column (GE Healthcare) as describe
above. The identity of each of the purified proteins was confirmed
by MALDI-TOF after trypsin digestion.
SARS-CoV nsp10/nsp16 co-expression was performed in E. coli
strain C41 (DE3) (Avidis SA, France) transformed with the pLysS
plasmid (Novagen). Cultures were grown at 37uC until the
OD600nm reached 0.6. Expression was induced by adding 50 mM
IPTG and 200 mg/L of anhydrotetracycline; then cells were
incubated for 16 h at 24uC. Bacterial pellets were treated as given
above and the soluble protein fraction incubated with Strep-
Tactin sepharose (IBA Biotagnology). After 3 washes, bound
proteins were eluted with 2.5 mM D-desthiobiotin in binding
buffer. After analysing the purified protein complex by SDS-
PAGE, the intensities of Coomassie-stained bands were quantified
using ImageJ.
RNA synthesis and purification
Short capped RNAs (
7MeGpppAC5, GpppAC5, were synthe-
sized in vitro using bacteriophage T7 DNA primase and were
purified by high-performance liquid chromatography (HPLC) as
previously described [69].
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the SARS-CoV genome (59 SARS-264) was prepared as follows. The
59 UTR of the SARS-CoV genome Frankfurt-1 was amplified by
PCR using the primers BamH1-T7phi2.5-59SARS (s) (CGGGATC-
CCAGTAATACGACTCACTATTATATTAGGTTTTTACCT-
ACCC) and EcoRI-SARS-264 (as) (GGAATTCCTTACCTT-
TCGGTCACAC) and cloned in the pUC18 (Fermentas) plasmid
after BamHI/EcoRI restriction-ligation procedure. The T7 class II
W2.5 promoter [43] was used (underlined in the primer) and the
second nucleotide of the genome (U) was substituted by a G. The
transcription matrix, was amplified by PCR (primers BamH1-
T7phi2.5-59SARS-AG (s) (CGGGATCCCAGTAATACGACT-
CACTATTAGATTAGGTTTTTACCTACCC) and SARS-264
(as) (CTTACCTTTCGGTCACAC)) and purified on agarose gel
using the QIAquick gel extraction kit (Qiagen). The AG-SARS-264
RNA substrate was synthesized by in vitro transcription using the
M E G A s h o r t s c r i p tT 7R N Ap o l y m e r a s ek i t( A m b i o n ) .A f t e rD N a s e
treatment (Ambion), and purification by RNeasy mini kit (Qiagen),
the AG-SARS-264 RNA was incubated for 1 h at 37uCw i t ht h eV V
capping enzyme (ScriptCap m7G Capping kit, Epicentre Biotechol-
ogies) in a reaction volume of 20 ml, either in the absence or in the
presence of AdoMet, according to the instructions of the manufac-
turer. 10 mCi [a-
32P]-GTP (PerkinElmer, Boston, MA) and 0.05 units
of inorganic pyrophosphatase (Sigma–Aldrich) were used. Radiola-
beled capped RNAs GpppAG-SARS-264 and
7MeGpppAG-SARS-
264 were then purified with the RNeasy mini kit (Qiagen).
Radioactive methyltransferase and filter binding assay
MTase activity assays were performed in 40 mM Tris-HCl,
pH 8.0, 5 mM DTT, 1 mM MgCl2 (only for nsp16/nsp10), 2 mM
7MeGpppAC5 or GpppAC5,1 0mM AdoMet, cand 0.03 mCi/ml
[
3H]AdoMet (GE Healthcare). In the standard assay, nsp10,
nsp14, and nsp16 were added at final concentrations of 1.2 mM,
50 nM, and 200 nM, respectively. The final concentrations of
nsp14 and nsp16 used in the assays were chosen so as to stay in the
linear phase of product formation after a 1 h incubation when
using GpppAC5 or
7MeGpppAC5 as substrates. A 6-fold molar
excess of nsp10 over nsp16 was chosen to achieve about 75% of
the maximal stimulation of 29O-MTase activity. Under these
conditions, the nsp14 and nsp10/nsp16 methylation reactions
converted similar amounts of substrate after 1 h of reaction. No
sign of protein inactivation was found up to the apparent end of
the linear phase. Reaction mixtures were incubated at 30uC and
stopped after the indicated times by a 10-fold dilution of the
reaction mixture in 100 mM ice-cold AdoHcy. Samples were kept
on ice and then transferred to glass-fiber filtermats (DEAE
filtermat; Wallac) by a Filtermat Harvester (Packard Instruments).
Filtermats were washed twice with 0.01 M ammonium formate,
pH 8.0, twice with water, and once with ethanol, dried, and
transferred into sample bags. Betaplate Scint (Wallac) scintillation
fluid was added, and the methylation of RNA substrates was
measured in counts per minute (cpm) by using a Wallac 1450
MicroBeta TriLux liquid scintillation counter. For inhibition
assays, we set up the reactions as described above with
7MeGpppAC5 for nsp16 and GpppAC5 for nsp14 in the presence
of 100 mM inhibitor candidate. Enzymes and RNA substrates
were mixed with the inhibitor before the addition of AdoMet to
start the reaction. The final concentration of DMSO in the
reaction mixtures was below 5%, and control reactions were
performed in presence of DMSO, which does not alter MTase
activity. Reaction mixtures were incubated at 30uC for 4 h and
analyzed by filter binding assay as described above. The IC50
(inhibitor concentration at 50% activity) value of AdoHcy,
sinefungin and ATA were determined using Kaleidagraph. Data
were adjusted to a logistic dose-response function, % activity =
100/(1+[I]/IC50)
b, where b corresponds to the slope factor and [I]
corresponds to the inhibitor concentration [73].
MTase assay on SARS-264 RNA and cap-methylation
analysis
MTase activity assays were performed in 40 mM Tris-HCl, pH 8.0,
5m MD T T ,1m MM g C l 2 (only for nsp16/nsp10), 50 mMA d o M e t
and 0.75 mM of capped AG-SARS-264 RNA at 30uC. The reaction
was stopped after different reaction times by incubating samples for
5m i na t7 0 uC. Samples were treated overnight with proteinase K
(0.1 mg/ml, Invitrogen). Proteinase K was inactivated by addition of
5m MP M S F ;a n dt h eR N A sw e r es u b s equently digested for 4 h with
nuclease P1 (0.05 U/ml, USBiological). Radiolabeled cap analog
standards were produced by direct digestion of the substrates leading to
GpppA and
7MeGpppA or digestion after methylation of the 29O-
position using VV 29O-MTase (ScriptCap 29O-methyltransferase kit,
Epicentre Biotechnologies) leading to GpppA2’OMe and
7MeGpp-
pA2’OMe. Digestion products were separated on polyethyleneimine
cellulose thin-layer chromatography (TLC) plates (Macherey Nagel)
using 0.45 M (NH4)2SO4 as mobile phase. After drying TLC plates,
the caps released by nuclease P1 were visualized using a phosphor-
imager (Fluorescent Image Analyzer FLA3000 (Fuji)).
Supporting Information
Text S1 Optimization of the nsp14 and nsp16/nsp10 MTase
activities on small capped RNA substrates GpppAC5 and
7
MeGpppAC5, respectively.
Found at: doi:10.1371/journal.ppat.1000863.s001 (0.03 MB
DOC)
Figure S1 Optimization of the nsp14 and nsp16/nsp10 MTase
activities on small capped RNA substrates. Nsp14 or nsp16/nsp10 were
incubated with GpppAC5 (in grey) or
7MeGpppAC5 (in black),
respectively. Themethyltransfer totheRNAsubstrateswasdetermined
after 30 min (panels A, C to E) or 1 h (panel B) by filter-binding assay.
Data represent meanvaluesofthree independentexperiments. Panel A:
The pH dependence of the nsp14 N7-MTase activity (50 mM) and the
29O-MTase activity of nsp16/nsp10 (200 nM/1.2 mM) was deter-
mined in 50 mM Bis-Tris (pH 5 to 7.5) and Tris-HCl buffer (pH 7 to
10). Values at determined pH optima were arbitrarily set to 100%.
Panel B: The effect of increasing nsp10 concentration was determined
on nsp14 (50 nM) and nsp16 (200 nM) MTase activities in Tris-HCl,
pH 8.0 containing 0 (nsp14) or 1 mM (nsp16/nsp10) MgCl2.V a l u e sa t
optimum nsp10/nsp16-MTase ratios were arbitrarily set to 100%.
Data points represent the mean of two independent experiments.
Panels C, D and E: Effect of increasing concentrations of MgCl2,
MnCl2,Z n C l 2 on the nsp14 N7-MTase (50 nM) and nsp16 29O-
MTase (200 nM) incubated with a 6-fold excess of nsp10. Values
obtained in Tris-HCl, pH 8.0; 5 mM DTT without ions for nsp14 and
with 1 mM MgCl2 for nsp16/nsp10 were arbitrarily set to 100%.
Found at: doi:10.1371/journal.ppat.1000863.s002 (0.46 MB EPS)
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